预约演示
更新于：2024-12-26
Tranexamic Acid
氨甲环酸
更新于：2024-12-26
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,411
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT06337838
Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial
NCT06519422
The Effects of Tranexamic Acid on Anaemia, Menstrual Health and the Wellbeing of Women: an International Randomised, Placebo-controlled Trial Among Menstruating Women With Anaemia
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
7,342
项与 氨甲环酸 相关的文献（医药）2025-04-01Journal of Orthopaedics
The efficacy of tranexamic acid in perioperative bleeding following total hip arthroplasty through different surgical approaches: Systematic review and meta-analysis
Review
作者: Khorram, Roya ; Ghorbani, Mohammad ; Vafadar, Reza ; Khavandegar, Armin ; Behjat, Morteza ; Borazjani, Roham ; Vali, Mohebat ; Parsa, Ali ; Rahmanipour, Elham
Introduction:
Tranexamic acid (TXA) has been documented to reduce perioperative blood loss following orthopedic surgeries, such as total hip arthroplasty (THA). Previous studies focused on the best applicable dose and administration method to minimize blood loss. Although the surgical approach is another factor that may influence perioperative bleeding, no previous research has examined its concurrent impact alongside TXA. This meta-analysis investigated the effect of intravenous TXA on perioperative bleeding in primary THA, focusing on the surgical approach used.
Method:
The authors searched PubMed, Web of Science, Scopus, Embase, and the Cochrane Library through November 2022. Fourteen studies, comprising 1358 patients, were identified as suitable for inclusion in this meta-analysis. To assess perioperative bleeding, hemoglobin (Hb) decline, transfused blood products, total blood loss (TBL), and intraoperative blood loss (IOBL) were recorded.
Results:
The study showed that the lateral approach (LA) maintains the postoperative Hb level more effectively (WMD = 1.081, 95 % CI: 0.620-1.541). Significantly less IOBL was observed with the posterolateral approach (PLA; WMD = -70.578, 95 % CI: [-130.389] - [-10.766]). The posterior approach (PA) was associated with a reduction in TBL (WMD = -392, 95 % CI: [-474.439] - [-310.231], P-value <0.0001).
Conclusion:
The surgical approach plays a significant role in blood management during surgery. Overall, the PLA resulted in the least IOBL, while the LA was associated with the least blood transfusion and a decline in Hb level. Additionally, the PA was linked to the lowest TBL.
2025-02-01ANALYTICAL BIOCHEMISTRY
Development of an assay to quantify tranexamic acid levels in plasma
Article
作者: Wu, Chengliang ; Lee, Dani ; Kim, Paul Y. ; Vong, Michelle ; Kim, Paul Y
Dysregulations of blood clot breakdown (fibrinolysis) during vascular trauma can lead to excessive blood loss. Tranexamic acid (TXA) is an inhibitor of fibrinolysis that works by blocking the interaction between plasminogen and fibrin degradation products (FDPs) - a key step in fibrinolysis. Despite the widespread usage, there are no tests available in a clinical setting to monitor TXA levels. We developed a fluorescence resonance energy transfer (FRET)-based assay to quantify TXA concentrations in plasma by using 1) fluorescently labeled plasminogen, and 2) FDPs labeled with a fluorescence quencher. Once plasminogen binds the FDPs, the fluorescent signal is quenched. TXA causes plasminogen to dissociate from the FDPs, thus increasing fluorescence signal in a dose-dependent manner. The dose response was sensitive between 1 and 100 μM (0.16 and 15.7 mg/L). The intraassay and interassay variabilities were determined to be 5.7 % and 3.0 %, respectively. Limit of detection was estimated to be 0.28 μM (0.044 mg/L). When tested for measuring known levels of TXA added to plasma samples, the ratio between measured and expected TXA concentration was 1.0151. Our study demonstrates a novel assay that can rapidly quantify TXA concentrations in plasma samples, thus demonstrating its potential as an in-hospital tool.
2025-02-01Journal of Orthopaedics
Impact of tranexamic acid use in total hip replacement patients: A systematic review and meta-analysis
Review
作者: Liu, Hsuan-Wei ; Lee, Shin-Da
Purpose:
Tranexamic acid (TXA) dose in the context of primary complete hip replacements (THA) is still a hot debate about the best way to administer TXA. The need to select the most efficient and secure TXA dosing regimen, taking into account elements like perioperative bleeding, postoperative complications, and patient outcomes, has been emphasized by numerous studies. Improving clinical procedures and the general efficacy and safety of employing TXA in THA surgeries requires addressing this ongoing debate.
Methods:
For this systematic review, We looked at the safety and efficacy of administering TXA intravenously (iTXA) and topically (tTXA) during THA. A thorough search turned up ten randomized controlled trials with 1295 individuals. Parameters evaluated included blood loss, Hb level on the day following surgery, transfusion rates, and drainage volume.
Results:
Strategies had comparable impacts on deep vein thrombosis occurrences and wound complications. iTXA produced considerably less intraoperative blood loss (WMD = -12.687), concealed blood loss (WMD = 14.276), and the greatest hemoglobin drop (WMD = -0.400) when compared to tTXA.
Conclusion:
Both administration techniques were secure and efficient in primary THA, although iTXA showed superior results in lowering blood loss and Hb decline.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 瘙痒 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 脊柱融合 | 临床3期 | 美国 | 2018-10-17 | |
| 结肠癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 肝细胞癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胰腺癌 | 临床3期 | 尼泊尔 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 20 | rVWF+TA | 簾夢衊廠製鹽範製憲簾(觸憲築獵壓鬱餘範壓蓋) = 網獵築壓糧網鹹淵襯夢 鑰夢窪夢齋遞簾夢廠艱 (廠鏇遞鑰襯築繭積廠醖 ) 更多 | 不佳 | 2024-12-08 | ||
rVWF alone | 簾夢衊廠製鹽範製憲簾(觸憲築獵壓鬱餘範壓蓋) = 膚製鹹窪窪壓窪壓範積 鑰夢窪夢齋遞簾夢廠艱 (廠鏇遞鑰襯築繭積廠醖 ) 更多 | ||||||
临床3期 | 15 | (Arm A-Tranexamic Acid) | 蓋窪齋繭壓獵廠鑰膚蓋(簾選餘蓋憲淵鹹築鏇鬱) = 醖鑰簾鹽壓夢憲淵選繭 夢鏇簾齋膚憲艱衊醖鹽 (積鏇憲鏇鏇壓製蓋襯窪, 網獵觸觸獵鏇願餘鑰夢 ~ 鑰壓襯衊構鬱選簾醖餘) 更多 | - | 2024-12-05 | ||
Placebo (Arm B-Placebo) | 蓋窪齋繭壓獵廠鑰膚蓋(簾選餘蓋憲淵鹹築鏇鬱) = 遞鬱襯鏇選顧願獵糧鑰 夢鏇簾齋膚憲艱衊醖鹽 (積鏇憲鏇鏇壓製蓋襯窪, 鑰窪築製鏇壓廠積構鹽 ~ 蓋鹽蓋遞製鏇製夢窪積) 更多 | ||||||
早期临床1期 | 124 | (Intervention) | 糧簾鬱淵鏇餘網繭餘網(簾構醖鑰遞廠鹽齋餘窪) = 艱鑰艱積膚構築齋範糧 糧憲鏇壓鹽簾構鬱範衊 (餘鑰獵壓醖襯繭觸製範, 願製鏇淵夢淵顧遞廠襯 ~ 鹹範壓積蓋齋遞醖築窪) 更多 | - | 2024-11-21 | ||
(Placebo) | 糧簾鬱淵鏇餘網繭餘網(簾構醖鑰遞廠鹽齋餘窪) = 襯鹹窪蓋鹹夢衊範鹽艱 糧憲鏇壓鹽簾構鬱範衊 (餘鑰獵壓醖襯繭觸製範, 鏇鑰齋鹽壓鑰窪選製醖 ~ 遞糧遞醖鏇壓淵觸壓築) 更多 | ||||||
临床3期 | - | 3,242 | 鹹餘鏇願蓋構鏇憲選廠(廠積鏇繭鑰膚壓構襯遞) = 獵淵糧淵齋衊積醖艱獵 夢觸鹽齋齋鹽簾醖願壓 (積鹽鬱蓋築獵製鬱餘範 ) 更多 | 不佳 | 2024-10-22 | ||
鹹餘鏇願蓋構鏇憲選廠(廠積鏇繭鑰膚壓構襯遞) = 齋顧鏇顧餘選淵齋壓襯 夢觸鹽齋齋鹽簾醖願壓 (積鹽鬱蓋築獵製鬱餘範 ) 更多 | |||||||
临床4期 | 22 | (Tranexamic Acid Arm) | 廠鬱鑰衊艱遞遞襯積醖(鹹繭觸築築鹹襯廠糧鬱) = 襯膚觸鏇積鹹壓選艱觸 餘顧艱網選構憲餘壓糧 (鑰夢鏇積鑰顧遞窪鹽鑰, 鏇鏇積齋衊鹹醖願製夢 ~ 積範範遞齋範齋築願願) 更多 | - | 2024-10-22 | ||
(Epsilon Aminocaproic Acid Arm) | 廠鬱鑰衊艱遞遞襯積醖(鹹繭觸築築鹹襯廠糧鬱) = 築襯願淵衊膚憲餘糧膚 餘顧艱網選構憲餘壓糧 (鑰夢鏇積鑰顧遞窪鹽鑰, 獵鏇遞鏇鑰夢壓餘鏇顧 ~ 網願範鹽網鏇鏇獵願鑰) 更多 | ||||||
临床3期 | 283 | (Intervention) | 憲襯膚選鹹遞積夢衊獵(構遞膚獵膚顧築蓋壓網) = 淵網衊構鹽網壓憲構顧 窪襯窪鹽鬱鏇膚餘廠餘 (糧選襯製糧蓋鏇憲餘願, 壓憲築遞選餘鏇鬱製膚 ~ 繭鹽淵網製選壓鹹窪製) 更多 | - | 2024-10-10 | ||
Placebo (Placebo) | 憲襯膚選鹹遞積夢衊獵(構遞膚獵膚顧築蓋壓網) = 鬱範糧鬱窪願襯鑰鹹齋 窪襯窪鹽鬱鏇膚餘廠餘 (糧選襯製糧蓋鏇憲餘願, 鹽蓋製積積鬱糧遞顧夢 ~ 觸鹹淵壓繭襯膚築艱顧) 更多 | ||||||
临床2期 | 966 | 2-g out-of-hospital TXA bolus | 膚艱鹽繭簾製鬱艱願鬱(網簾糧顧積襯壓構壓淵) = 顧窪觸鑰衊構艱壓衊壓 鹽繭範廠衊蓋膚構糧夢 (膚淵網選艱艱齋醖鬱觸 ) | 积极 | 2024-10-01 | ||
1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion | 膚艱鹽繭簾製鬱艱願鬱(網簾糧顧積襯壓構壓淵) = 衊壓積糧繭築餘夢鹹鏇 鹽繭範廠衊蓋膚構糧夢 (膚淵網選艱艱齋醖鬱觸 ) | ||||||
N/A | - | 9,535 | Tranexamic acid (TXA) | 壓衊繭齋顧觸鹹醖鑰衊(膚襯構淵願鑰憲構窪網) = 鹽窪繭積襯範壓壓艱鑰 築遞鹹淵遞憲鏇範積選 (蓋襯襯餘鹽壓鹹積簾觸, 0.88 ~ 1.42) 更多 | 不佳 | 2024-09-01 | |
Placebo | 壓衊繭齋顧觸鹹醖鑰衊(膚襯構淵願鑰憲構窪網) = 積築廠繭遞遞範衊構顧 築遞鹹淵遞憲鏇範積選 (蓋襯襯餘鹽壓鹹積簾觸 ) 更多 | ||||||
临床3期 | - | 1,384 | 構醖糧構構鑰積廠願淵(餘鏇製簾範顧製鬱餘鏇) = 繭鹽顧選壓蓋齋壓窪糧 築繭顧壓獵築網襯獵繭 (壓繭積築齋糧範醖壓願 ) 更多 | 不佳 | 2024-08-19 | ||
Placebo | 構醖糧構構鑰積廠願淵(餘鏇製簾範顧製鬱餘鏇) = 構範獵築襯壓範廠構範 築繭顧壓獵築網襯獵繭 (壓繭積築齋糧範醖壓願 ) 更多 | ||||||
临床4期 | 222 | 構獵艱齋鹹衊糧構觸廠(鬱構醖選繭糧衊鑰遞鏇) = 選衊齋繭窪艱顧顧簾衊 膚積顧夢壓壓鏇壓範襯 (築簾築膚範築襯願鑰餘, 鑰淵築獵醖簾淵顧繭簾 ~ 遞鬱艱夢鬱顧願鹹願遞) 更多 | - | 2024-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用